澳门葡京网赌游戏 has entered into a licensing agreement with Redx制药 for RXC006, 口服, small molecule preclinical porcupine inhibitor. The Company will take the molecule forward into clinical development targeting fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), 一种慢性, 进步, irreversible and usually fatal, 间质性肺病,1 for which there are limited treatment options available.
Porcupine inhibition is a potential novel approach to target fibrotic pathways earlier compared with other mechanisms in development for IPF.
Mene Pangalos, Executive Vice President, 澳门葡京赌博游戏 R&D, 澳门葡京网赌游戏 said: “Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new therapies are urgently needed. We look forward to progressing this porcupine inhibitor into clinical trials as a novel approach to supress Wnt signalling and potentially modify fibrotic disease processes.”
丽莎安森, 首席执行官, Redx制药, commented: “We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is a real patient need. 本协议, where 澳门葡京网赌游戏 will license this first-in-class porcupine inhibitor for IPF and progress it into development, 突出了, 再一次, Redx’s ability to generate molecules that have significant potential as novel medicines.”
RXC006 has the potential to slow or prevent fibrosis in IPF and potentially other fibrotic diseases. The Company anticipates entering clinical development in 2021.
IPF
IPF causes shortness of breath and 进步 damage of the lung, resulting in life-threatening complications such as respiratory failure. IPF progression varies greatly between patients but over time, most experience increasing respiratory symptoms, increased scarring of the lungs and a gradual decline in lung function. ‘Idiopathic’ refers to the unknown cause of disease, however there is proof of genetic predisposition in some patients.1
RXC006 and porcupine inhibition
在肾脏动物模型中, 肝、肺纤维化, RXC006 showed inhibition of the porcupine enzyme resulting in anti-fibrotic effects.2 Porcupine inhibition is a novel anti-fibrotic approach that suppresses Wnt ligand secretion from profibrotic cells. Wnt ligands regulate multiple aspects of disease biology and are highly expressed in diseases such as idiopathic pulmonary fibrosis.
澳门葡京网赌游戏
澳门葡京网赌游戏 (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, CVRM, 和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit 澳门葡京网赌游戏.com and follow the Company on 推特 @澳门葡京网赌游戏.
联系人
For details on how to contact the 投资者关系 Team, please 点击这里. 媒体联系人: 点击这里.
参考文献
1. Lederer, D J and Martinez F J. Idiopathic Pulmonary Fibrosis. [英]医学. 2018;378:1811-23.
2. Redx网站:http://www.redxpharma.com/programmes/rxc006-porcupine-fibrosis/